Immune-related gene expression profiling of Epithelial Ovarian Cancer after Neoadjuvant chemotherapy

We explore the potential of immune-associated expression profiles in a series of Epithelial Ovarian Cancer (EOC) patients undergoing neoadjuvant chemotherapy (NACT), comparing primary lesions before patients underwent carboplatin/paclitaxel-based NACT (so-called ´biopsy samples´) and interval debulking surgery (IDS) samples from residual lesions after treatment with chemotherapy (so-called ´surgery samples´). nCounter immune profiling was used to carry out an immune-related gene expression analysis in 27 patients with EOC, comparing biopsy and surgery samples. Biopsy samples were collected from primary lesions before EOC patients underwent carboplatin/paclitaxel-based neoadjuvant chemotherapy, according to availability. Surgery samples were extracted from residual lesions after treatment with chemotherapy, according to availability. We analyzed only biopsy samples from 8 patients, only surgery samples from 2 patient and paired biopsy-surgery samples from 17 patients. We also compared responder and non-responder patients using the chemotherapy response score (CRS). This score stratifies patients with no/minimal tumor response (CRS1), partial response (CRS2) and total/near-total tumor response (CRS3) to NACT.